<DOC>
	<DOCNO>NCT02053597</DOCNO>
	<brief_summary>Recently , rise trend delay childbearing hence woman diagnose breast cancer complete family . Given continuous decline recurrence death secondary breast cancer reassure data safety pregnancy follow breast cancer woman inquire possibility preserve fertility follow chemotherapy . The challenge remain use regimen devoid cyclophosphamide , effective standard regimen incorporate cyclophosphamide . The combination doxorubicin ( 50 mg/m2 ) paclitaxel ( 200 mg/m2 ) ( AP ) follow 12 week paclitaxel ( 80 mg/m2 ) ( P ) emerge treatment option convince result regard effectiveness early setting , could potentially associate less ovarian toxicity devoid cyclophosphamide .</brief_summary>
	<brief_title>TRIal evalUating Menstrual Ovarian Function Young Breast Cancer Patients Treated With cycloPHosphamide-free Regimen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Age ≤ 40 year . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . 3 . Nonmetastatic primary invasive carcinoma breast eligible adjuvant neoadjuvant chemotherapy . 4 . Negative estrogen ( ER ) progesterone receptor ( PgR ) status . 5 . Baseline leave ventricular ejection fraction ( LVEF ) ≥50 % measure echocardiogram MUGA . 6 . Interested maintain menstrual and/or ovarian function follow completion chemotherapy . 7 . Known HER2/neu status . 8 . Negative pregnancy test within 14 day prior start chemotherapy . 9 . Adequate hematologic , hepatic renal function . 10 . Signed informed consent . 1 . History prior malignant disease ( breast nonbreast ) nonmalignant condition treat chemotherapy , pelvic irradiation therapy could potentially affect ovarian function . 2 . Previous history amenorrhea &gt; 3 month within last 2 year ( exclude pregnancy ) . 3 . Ovarian insufficiency define serum FSH &gt; 20 IU/L local laboratory , anytime menstrual cycle . 4 . Any ovarian pathology abnormality screen pelvic ultrasound , except functional follicular cyst . 5 . Pregnant breastfeeding patient . 6 . Inability unwillingness use effective contraception 3 month last dose study medication . Effective method include follow : nonhormonal intrauterine device , barrier method condom , diaphragm also conjugation spermicidal jelly , total abstinence . Oral , injectable , implant hormonal contraceptive allow . 7 . Concurrent use cytotoxic hormonal agent , namely GnRH agonist . 8 . Prior preexist peripheral neuropathy cause , include diabetes mellitus , alcohol abuse , HIV infection , autoimmune hereditary neuropathy , amyloidosis , hypothyroidism , vitamin deficiency . 9 . Serious cardiac illness , uncontrolled hypertension medical condition would affect administration chemotherapy compliance study procedure . 10 . Known sensitivity study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Primary breast cancer</keyword>
	<keyword>Young woman</keyword>
	<keyword>Ovarian function</keyword>
	<keyword>Sexual function</keyword>
	<keyword>Eligible adjuvant neoadjuvant chemotherapy</keyword>
	<keyword>Negative hormone-receptor status</keyword>
</DOC>